Literature DB >> 32672335

Effect of preoperative chemoradiotherapy on the immunological status of rectal cancer patients.

Kazuaki Yasui1,2, Ryota Kondou1, Akira Iizuka1, Haruo Miyata1, Emiko Tanaka1, Tadashi Ashizawa1, Takeshi Nagashima3,4, Keiichi Ohshima5, Kenichi Urakami3, Masatoshi Kusuhara6, Koji Muramatsu7, Takashi Sugino7, Ken Yamguchi8, Keita Mori9, Hideyuki Harada2, Tetsuo Nishimura2, Hiroyasu Kagawa10, Yushi Yamakawa10, Hitoshi Hino10, Akio Shiomi10, Yasuto Akiyama1.   

Abstract

The aim of the study was to investigate the effect of chemo-radiation on the genetic and immunological status of rectal cancer patients who were treated with preoperative chemoradiotherapy (CRT). The expression of immune response-associated genes was compared between rectal cancer patients treated (n = 9) and not-treated (n = 10) with preoperative CRT using volcano plot analysis. Apoptosis and epithelial-to-mesenchymal transition (EMT) marker genes were analysed by quantitative PCR (qPCR). Other markers associated with the tumor microenvironment (TME), such as tumor-infiltrating lymphocytes (TIL) and immune checkpoint molecules, were investigated using immunohistochemistry (IHC). The clinical responses of preoperative CRT for 9 rectal cancer patients were all rated as stable disease, while the pathological tumor regression score (TRG) revealed 6 cases of grade2 and 3 cases of grade1. According to the genetic signature of colon cancers, treated tumors belonged to consensus molecular subtype (CMS)4, while not-treated tumors had signatures of CMS2 or 3. CRT-treated tumors showed significant upregulation of EMT-associated genes, such as CDH2, TGF-beta and FGF, and cancer stem cell-associated genes. Additionally, qPCR and IHC demonstrated a suppressive immunological status derived from the upregulation of inflammatory cytokines (IL-6, IL-10 and TGF-beta) and immune checkpoint genes (B7-H3 and B7-H5) and from M2-type macrophage accumulation in the tumor. The induction of EMT and immune-suppressive status in the tumor after strong CRT treatment urges the development of a novel combined therapy that restores immune-suppression and inhibits EMT, ultimately leading to distant metastasis control.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Entities:  

Keywords:  chemoradiotherapy (CRT); consensus molecular subtype (CMS); epithelial-to-mesenchymal transition (EMT); tumor microenvironment (TME); tumor-infiltrating lymphocytes (TIL)

Mesh:

Substances:

Year:  2020        PMID: 32672335      PMCID: PMC7482156          DOI: 10.1093/jrr/rraa041

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  37 in total

1.  Radiation induces epithelial-mesenchymal transition in colorectal cancer cells.

Authors:  Aya Kawamoto; Takeshi Yokoe; Koji Tanaka; Susumu Saigusa; Yuji Toiyama; Hiromi Yasuda; Yasuhiro Inoue; Chikao Miki; Masato Kusunoki
Journal:  Oncol Rep       Date:  2011-10-03       Impact factor: 3.906

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.

Authors:  Eiji Shinto; Kazuo Hase; Yojiro Hashiguchi; Akinori Sekizawa; Hideki Ueno; Atsushi Shikina; Yoshiki Kajiwara; Hirotoshi Kobayashi; Megumi Ishiguro; Junji Yamamoto
Journal:  Ann Surg Oncol       Date:  2014-02-25       Impact factor: 5.344

4.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Authors:  Claus Rödel; Ullrich Graeven; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Dirk Arnold; Ralf-Dieter Hofheinz; Michael Ghadimi; Hendrik A Wolff; Marga Lang-Welzenbach; Hans-Rudolf Raab; Christian Wittekind; Philipp Ströbel; Ludger Staib; Martin Wilhelm; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer; Torsten Liersch
Journal:  Lancet Oncol       Date:  2015-07-15       Impact factor: 41.316

5.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.

Authors:  Ralf-Dieter Hofheinz; Frederik Wenz; Stefan Post; Axel Matzdorff; Stephan Laechelt; Jörg T Hartmann; Lothar Müller; Hartmut Link; Markus Moehler; Erika Kettner; Elisabeth Fritz; Udo Hieber; Hans Walter Lindemann; Martina Grunewald; Stephan Kremers; Christian Constantin; Matthias Hipp; Gernot Hartung; Deniz Gencer; Peter Kienle; Iris Burkholder; Andreas Hochhaus
Journal:  Lancet Oncol       Date:  2012-04-13       Impact factor: 41.316

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.

Authors:  Tadashi Ashizawa; Akira Iizuka; Chizu Nonomura; Ryota Kondou; Chie Maeda; Haruo Miyata; Takashi Sugino; Koichi Mitsuya; Nakamasa Hayashi; Yoko Nakasu; Kouji Maruyama; Ken Yamaguchi; Ikumi Katano; Mamoru Ito; Yasuto Akiyama
Journal:  Clin Cancer Res       Date:  2016-07-25       Impact factor: 12.531

Review 8.  Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer.

Authors:  V J Findlay; C Wang; D K Watson; E R Camp
Journal:  Cancer Gene Ther       Date:  2014-05-02       Impact factor: 5.987

9.  Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.

Authors:  Keiichi Ohshima; Keiichi Hatakeyama; Takeshi Nagashima; Yuko Watanabe; Kaori Kanto; Yuki Doi; Tomomi Ide; Yuji Shimoda; Tomoe Tanabe; Sumiko Ohnami; Shumpei Ohnami; Masakuni Serizawa; Koji Maruyama; Yasuto Akiyama; Kenichi Urakami; Masatoshi Kusuhara; Tohru Mochizuki; Ken Yamaguchi
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

10.  Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.

Authors:  Shinji Matsutani; Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsunari Fukuoka; Shigetomi Nakao; Kosei Hirakawa; Masaichi Ohira
Journal:  Cancer Sci       Date:  2018-03-25       Impact factor: 6.716

View more
  6 in total

1.  A three-phase trans-ethnic study reveals B7-H3 expression is a significant and independent biomarker associated with colon cancer overall survival.

Authors:  Yuan Gao; Yu Xu; Meiqin Gao; Aimin Huang; Pan Chi
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  Poor nutrition and sarcopenia are related to systemic inflammatory response in patients with rectal cancer undergoing preoperative chemoradiotherapy.

Authors:  Shinya Abe; Hiroaki Nozawa; Kazushige Kawai; Kazuhito Sasaki; Koji Murono; Shigenobu Emoto; Junko Kishikawa; Tsuyoshi Ozawa; Yuichiro Yokoyama; Yuzo Nagai; Hiroyuki Anzai; Hirofumi Sonoda; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2021-10-11       Impact factor: 2.571

Review 3.  Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review.

Authors:  Edgaras Smolskas; Goda Mikulskytė; Ernestas Sileika; Kestutis Suziedelis; Audrius Dulskas
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

Review 4.  Immunity, immunotherapy, and rectal cancer: A clinical and translational science review.

Authors:  Ebunoluwa E Otegbeye; Jonathan B Mitchem; Haeseong Park; Aadel A Chaudhuri; Hyun Kim; Matthew G Mutch; Matthew A Ciorba
Journal:  Transl Res       Date:  2020-12-08       Impact factor: 7.012

5.  The immune microenvironment landscape shows treatment-specific differences in rectal cancer patients.

Authors:  Cristina Graham Martínez; Yari Barella; Sonay Kus Öztürk; Marleen Ansems; Mark A J Gorris; Shannon van Vliet; Corrie A M Marijnen; Iris D Nagtegaal
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

6.  Debating Pros and Cons of Total Neoadjuvant Therapy in Rectal Cancer.

Authors:  Francesco Sclafani; Claudia Corrò; Thibaud Koessler
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.